ArticleMedical oncology (Northwood, London, England)2025
GLYR1-mediated downregulation of lncRNA HSD11B1-AS1 promotes proliferation, migration, and invasion of breast cancer cells.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) play important roles in the occurrence and development of multiple cancers, but the role of lncRNAs in breast cancer has not been fully elucidated. We integrated data mining, bioinformatics analysis, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) to pinpoint key lncRNAs that modulate breast cancer development. In vitro functional assays evaluated the impact of lncRNA 11β-hydroxysteroid dehydrogenase type 1-antisense RNA 1 (HSD11B1-AS1) on breast cancer cells proliferation, migration, and invasion. Interactions between HSD11B1-AS1 and Glyoxylate Reductase 1 Homolog (GLYR1) within breast cancer cells were confirmed through bioinformatics prediction, chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays. Rescue experiments substantiated the involvement of GLYR1 in breast cancer advancement through the regulation of HSD11B1-AS1. HSD11B1-AS1 is markedly downregulated in breast cancer tissues and cell lines, correlating with an unfavorable prognosis for patients. Functional assays revealed that the suppression of HSD11B1-AS1 notably amplified the proliferation, migration, and invasive capabilities of breast cancer cells. Conversely, the overexpression of HSD11B1-AS1 significantly curtailed the proliferation, migration, and invasion of breast cancer cells. Mechanistically, GLYR1 directly binds to the HSD11B1-AS1 promoter and repressess its transcription, thereby enhancing the malignant behaviors of breast cancer cells, including proliferation, migration, and invasion. GLYR1-mediated suppression of HSD11B1-AS1 drives breast cancer progression. The GLYR1/HSD11B1-AS1 axis may represent a promising avenue for diagnostic biomarkers and therapeutic intervention in breast cancer.
Indexed as
Identifiers
41217560What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.